Can Monoclonal Antibodies Reduce Your Risk of Getting COVID-19?

Our immune system is a pretty powerful tool capable of fighting off everyday infections. But sometimes, when faced with more severe illnesses like cancer, our immune system could use an additional boost. One such boost comes in the form of lab-made monoclonal antibodies.

Infections disease specialist Tricia Bravo, MD, breaks down this very scientific-sounding term and explains how monoclonal antibodies were used earlier in the pandemic to prevent severe COVID-19 infections in people who were at higher risk for serious illness.

What are monoclonal antibodies?

When you’re exposed to an infection, your body makes specific proteins called antibodies that are designed to fight off that infection. When you no longer have that infection, your body continues to produce some of those antibodies in case the infection returns.

“Antibodies are basically proteins that your body makes to fight a specific infection,” explains Dr. Bravo.

Monoclonal antibodies are lab-made antibodies that mimic what your natural antibodies are able to do, but they tend to work faster with more immediate results. Monoclonal antibodies are most often used as a form of targeted therapy for specific kinds of cancer, but they’ve also been used throughout the pandemic to help fight off COVID-19.

“It’s very specific ammunition to fight particular infectious organisms,” Dr. Bravo adds.

How are monoclonal antibodies used to treat COVID-19?

Neutralizing monoclonal antibodies are no longer used to treat COVID-19 in the U.S. because they’re not as effective against currently circulating omicron subvariants.

Currently in the U.S., the main treatment options that target COVID-19 directly are these antiviral medications:

• Paxlovid™ (a combination of two medications, nirmatrelvir and ritonavir).
• Lagevrio™ (molnupiravir).
• Veklury® (remdesivir) through an IV infusion.

These are available for people with mild to moderate COVID-19 infection who are at high risk for progressing to severe infection. Remdesivir is also a recommended treatment strategy in conjunction with steroids for certain people who are hospitalized with severe illness.

Earlier in the pandemic, monoclonal antibodies like Evusheld™ (tixagevimab and cilgavimab) were once used as a preventive measure against COVID-19. These neutralizing monoclonal antibodies have a different mechanism of action from antivirals.

“That means neutralizing monoclonal antibodies work differently from antiviral medications by attaching to the spike protein on the surface of the COVID-19 virus and preventing it from infecting your cells,” explains Dr. Bravo. “Antiviral medications, on the other hand, stop the virus from making copies of itself and reduces the spread of infection.”

Now, the U.S. Food and Drug Administration (FDA) has withdrawn emergency use authorization for monoclonal antibodies that have been previously used as treatment.

The monoclonal antibodies that are no longer authorized in the U.S. (but may be authorized in other areas outside of the U.S.) include:

• Bamlanivimab/Etesevimab.
• Bebtelovimab.
• Evusheld (tixagevimab and cilgavimab).
• REGEN-COV® (casirivimab and imdevimab).
• Sotrovimab.

Other monoclonal antibodies, like Actemra® (tocilizumab), are only used as treatment in the U.S. for people who are hospitalized with severe COVID-19 infection who meet the following criteria:

• Age 2 and older.
• Have tested positive for COVID-19.
• Have been hospitalized.
• Receiving systemic corticosteroids.
• Receiving supplemental oxygen.

This medication doesn’t target the coronavirus directly, but it’s an anti-inflammatory that stops your immune system from becoming overreactive to the virus. This medication has also been used to treat other inflammatory conditions like rheumatoid arthritis.

The recommendations for COVID-19 treatments and the use of monoclonal antibodies changes often to meet the demand of up-and-coming variants. For the most up-to-date information, the FDA offers a list of treatments that have been given emergency use authorization (EUA) for treating COVID-19. The National Institutes of Health (NIH) continues to update its guidelines with new effective treatments, alongside a list of old treatments that have become ineffective. And for people outside of the U.S., the World Health Organization (WHO) offers its own set of guidelines on which treatments are recommended.

How are monoclonal antibodies given?

Monoclonal antibodies are only given through an IV or as a subcutaneous injection (a shot). That means, in order to receive them, you need to be seen in a medical setting, which limits the overall availability of the treatment.

When used as a treatment for COVID-19, Actemra is given through a single 60-minute IV infusion.

Monoclonal antibodies vs. vaccines

Don’t think of monoclonal antibodies as an alternative to the COVID-19 vaccine. Dr. Bravo stresses that getting vaccinated is still your body’s single best protection against contracting severe COVID-19. That’s true even if you’re immunocompromised.

“I can’t emphasize enough the importance of vaccines,” she says. “They offer a much better kind of protection and a much more lasting protection than you can get with monoclonal antibodies.”